AJP - Renal Physiology, Vol 258, Issue 3 756-F759, Copyright © 1990 by American Physiological Society

ARTICLES

The 11 beta-OHSD inhibitor, carbenoxolone, enhances Na retention by aldosterone and 11-deoxycorticosterone

D. J. Morris and G. W. Souness
Department of Pathology and Laboratory Medicine, Miriam Hospital, Providence, Rhode Island.

Carbenoxolone sodium, CS, a liquorice derivative associated with hypertension and sodium retention, has been demonstrated to inhibit 11 beta-hydroxysteroid dehydrogenase, an enzyme that metabolizes cortisol and corticosterone to their respective inactive 11-dehydro products (cortisone and 11-dehydrocorticosterone). It has been proposed that the increased bioavailability of unmetabolized corticosterone and cortisol following 11 beta-OHSD inhibition allows these steroids to act on renal mineralocorticoid receptors to elicit the mineralocorticoid action. Here we describe how CS amplifies the antinatriuretic activity of aldosterone and deoxycorticosterone; the latter steroid is of particular importance in that it does not possess a hydroxyl group at the C-11 position in the steroid ring, indicating that another mechanism(s) in addition to 11 beta-OHSD inhibition is responsible for the amplification of the action of deoxycorticosterone.

This article has been cited by other articles:

				M. E. Ullian, C. J. Robinson, C. T. B. Evans, J. Z. Melnick, and W. R. Fitzgibbon Role of Citrate Synthase in Aldosterone-Mediated Sodium Reabsorption Hypertension, April 1, 2000; 35(4): 875 - 879. [Abstract] [Full Text] [PDF]

				D. J. Morris, S. A. Latif, M. D. Rokaw, C. O. Watlington, and J. P. Johnson A second enzyme protecting mineralocorticoid receptors from glucocorticoid occupancy Am J Physiol Cell Physiol, May 1, 1998; 274(5): C1245 - C1252. [Abstract] [Full Text] [PDF]